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ABSTRACT 
 
Purpose To investigate associations between maternal use of selected medications during early 
pregnancy and the risk of hypospadias in male infants. 
 
Methods We used data from the National Birth Defects Prevention Study, a multi-site, 
population-based, case-control study. We analyzed data from 1,537 case infants with second or 
third degree isolated hypospadias and 4,314 male control infants born from 1997-2007. Exposure 
was based on reported use of any prescription or over-the-counter medication or herbal product, 
for which there were at least 5 exposed cases, from 1 month before to 4 months after conception, 
excluding topicals, vitamins, minerals, and products for which the components were unknown. 
Adjusted odds ratios (aORs) and 95% confidence intervals (CI) were estimated using 
multivariable logistic regression, adjusting for several confounders.     
 
Results Of the 195 medication components with at least 5 exposed cases, 89 components met the 
inclusion criteria and were assessed-28 herbal and 61 non-herbal components. Hypospadias was 
associated with reported use of cephalexin (aOR 3.06; 95% CI 1.02, 9.18), phenylpropanolamine 
HCl (aOR 2.68; 95% CI 1.06, 6.80), and ibuprofen (aOR 1.16; 95% CI 1.00, 1.34), in primary 
analyses.  
 
Conclusions We replicated a previously observed association between maternal exposure to 
phenylpropanolamine HCl and hypospadias. The associations with cephalexin and ibuprofen 
have not previously been reported. Given the exploratory nature of the analyses, these results 
should be considered hypothesis-generating. Better understanding of the potential fetal effects 
will allow clinicians and women of childbearing age to make more informed decisions regarding 
the use of medications during pregnancy. 
 
 
INDEX WORDS: medications during pregnancy, hypospadias, birth defects, drug safety 
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CHAPTER I 
INTRODUCTION 
1.1 Background 
 Birth defects are structural or functional abnormalities that are present at birth and cause 
physical or mental disability.
1
 A structural birth defect results when some part of the body, 
internal or external, is missing or malformed.
2
 Functional birth defects are related to a problem 
with how a body part or body system works and often lead to developmental disabilities.
1
 
 Birth defects affect approximately 3% of all live births in the United States and are an 
important public health issue.
3
 Birth defects are a leading cause of infant mortality; in 2008 birth 
defects contributed to more than 5,600 infant deaths in the U.S., accounting for 20.1% of all 
infant deaths.
4
 Furthermore, birth defects substantially impact health care costs. The cost of 
lifetime care for infants born in 1992, with one or more of 17 of the most clinically significant 
structural birth defects in the United States, was an estimated $6 billion.
5
  
 The causes of approximately 60-70% of birth defects are currently unknown; however 
genetic and environmental factors have been identified as potential risk factors for some birth 
defects.
2
 Risk factors that have been identified for having a child with a birth defect include 
maternal age, certain medical conditions, and maternal use of certain medications, illicit drugs, 
cigarettes, or alcohol during pregnancy.
6
 
 Some medications are known or strongly suspected teratogens, including thalidomide, 
isotretinoin, valproic acid, and mycophenolate mofetil. Use of medications that are known to 
cause birth defects is at times necessary in the treatment of women of childbearing age, for 
conditions such as epilepsy and immune suppression after organ transplantation.
7
 In the United 
States alone, women of childbearing age receive 11.7 million prescriptions for potentially 
teratogenic medications each year.
8
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In the United States, medication use is highly prevalent in women of childbearing age, 
with more than 80% of pregnant women taking over-the-counter (OTC) or prescription drugs 
during pregnancy, 
9
 despite the fact that little data exist on risks or safety of most medications 
used by pregnant women.
10–13
  The overall prevalence of herbal use anytime during pregnancy 
was recently estimated at 9.4%.
14
 Unlike prescription and newer OTC medications, herbal 
products are usually marketed without the benefit of clinical trials to demonstrate either efficacy 
or safety because under the Dietary Supplement Health and Education Act of 1994, the 
responsibility for ensuring safety before marketing belongs to manufacturers.
15
 
Many pregnant women require drug therapy due to pregnancy-induced conditions such as 
nausea and vomiting, chronic conditions diagnosed before pregnancy, or acute conditions that 
develop during pregnancy. However, medication use during pregnancy poses a potential risk to 
both the mother and the fetus. Pregnancy is associated with physiologic and pharmacokinetic 
changes that potentially alter the dosing, effectiveness, and ultimately, the safety of many 
drugs.
11
  Use of medications during pregnancy has been associated with an increased risk of 
many different types of birth defects, including hypospadias, a common birth defect in male 
offspring.
16–19
    
1.2 Purpose of Study  
The main objective of this study was to investigate associations between maternal use of 
selected medications, including prescription, over-the-counter, and herbal preparations, during 
the periconceptional period and early pregnancy and the risk of second- or third-degree 
hypospadias in male infants. This analysis will help to identify medications that may increase the 
risk of hypospadias in males. Identifying medications that may increase the risk of having a baby 
3 
 
with hypospadias will give researchers a better idea of what causes this birth defect and 
subsequently, findings may help inform directions for future preventive efforts. 
1.3 Research Questions  
1. Are there associations between maternal use of selected prescription, over-the-counter, 
and herbal preparations, during the periconceptional period and early pregnancy, and the 
risk of second- or third-degree hypospadias in male infants? 
2. Are there associations between maternal use of prescription, over-the-counter, and herbal 
preparations, during the periconceptional period and early pregnancy, and the risk of 
second- or third-degree hypospadias in male infants, after adjusting for potential 
confounding factors? 
3. Are there associations between maternal use of prescription, over-the-counter, and herbal 
preparations, during the periconceptional period and early pregnancy, and the risk of 
second- or third-degree hypospadias in male infants, after excluding infants with a 
positive family history of hypospadias? 
4. Are there associations between maternal use of prescription, over-the-counter, and herbal 
preparations, during the periconceptional period and early pregnancy, and the risk of 
second- or third-degree hypospadias in male infants, after excluding low birth weight and 
multiple births? 
5. Are there associations between maternal use of prescription, over-the-counter, and herbal 
preparations, during the periconceptional period and early pregnancy, and the risk of 
second- or third-degree hypospadias in male infants, after excluding mothers who 
reported illicit drug use? 
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CHAPTER II 
REVIEW OF THE LITERATURE 
In this chapter, support of this study’s research questions and variables of interest are 
synthesized from the scientific literature. The literature review examines hypospadias, including 
a description of the condition, penile embryology, epidemiology, risk factors and etiology, and 
medication use during pregnancy and risk of hypospadias.    
2.1 Description of Hypospadias 
 Hypospadias is the result of abnormal development of the penis that leaves the urethral 
meatus proximal to its normal glanular position anywhere along the penile shaft, scrotum, or 
perineum.
20
 Abnormalities commonly associated with hypospadias include ventral curvature of 
the penis known as chordee, a “hooded” incomplete prepuce, and an abortive corpora 
spongiosum.
21
  
The term hypospadias stems from the Greek words hypo, which means “below,” and 
spadon, which means “hole.”22 Hypospadias, as a congenital anomaly, was first documented in 
the medical literature by Heliodurus, Antyllus, and Galen in the 1
st
 and 2
nd
 centuries AD. Greek, 
Roman, and Egyptian texts from this time period have been found to contain references to 
hypospadias and hypospadias repairs, with the early writers documenting the abnormal urethral 
meatus below the corona of the glans and exhibiting concern regarding proper voiding and the 
ability to procreate.
23
 
   Hypospadias is classified by the location of the urethral meatus. Meatal position may be 
classified as anterior or distal, middle, and posterior or proximal, with more anatomically 
specific subgroups being applied further.
24
 Anterior hypospadias is described as glandular, 
coronal, or distal. Glandular hypospadias is when the meatus is on the ventral surface of the 
glans penis, in coronal the meatus is in the balanopenile furrow, and distal is when the meatus is 
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in the distal third of the penile shaft. Middle hypospadias is along the middle third of the penile 
shaft and posterior hypospadias extends through the proximal third of the penile shaft to the 
perineum and is described as posterior penile, penoscrotal, scrotal, or perineal. Posterior penile 
hypospadias is when the meatus is at the base of the shaft, in penoscrotal it is at the base of the 
shaft in front of the scrotum, in scrotal it is on the scrotum or between the genital swellings, and 
in perineal it is behind the scrotum or behind the genital swellings.
25
  
Hypospadias classification in terms of degrees was described by CK Smith in 1938, in 
which the first degree locates the meatus from the corona to the distal shaft, the second degree 
from the distal shaft to the penoscrotal junction, and the third degree is from the penoscrotal 
junction to the perineum.
26
 Classification systems do not take into account the degree of penile 
curvature or other individual features or anomalies; therefore, they do not always correlate 
directly with the severity of the condition or extent of surgical repair that might be required.
27
 
Treatment of hypospadias consists of surgical repair of the defect to construct a 
functional and cosmetically sound sexual organ, without penile curvature, and with a 
repositioned meatus to allow voiding while standing.
20,25,28
 Repair can be performed in otherwise 
healthy infants between 4 -8 months of age as an outpatient procedure.
27
 The majority of 
hypospadias cases can be repaired successfully in one-stage, however in some challenging cases 
with severe chordee and a proximal meatus, a two-stage repair is required.
20
 Ultimately though, 
the technique used in the treatment of hypospadias is based upon glanular size, degree of 
chordee, and location of the meatus and must be tailored to the child.
23
 Fistula formation, 
urethral stricture, a proximal meatus, residual curvature, and cosmetic abnormalities are all 
complications that can result from hypospadias surgery.
28
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2.2 Penile Embryology  
 The human penis goes through a natural state of hypospadias during its development 
from a primitive, undifferentiated structure into a fully differentiated penile urethra.
27
 Penile and 
urethral development is a complex developmental process involving genetic programming, cell 
differentiation, hormonal signaling, enzyme activity, and tissue remodeling.
25
 
 The hindgut and future urogenital system reach the surface of the embryo at the cloacal 
membrane on the ventral surface by the end of the first month of gestation. The urorectal septum 
divides the cloacal membrane into two halves, a posterior or anal half and an anterior half called 
the urogenital membrane. Three protuberances appear around the urogenital membrane, with the 
most cephalad protruberance being the genital tubercle and the other two protruberances are the 
genital swellings that are located on each side of the urogenital membrane.
29
 
 At 8 weeks gestation, the external genitalia of both male and female embryos are 
indistinguishable, with both having the midline genital tubercle just above a urogenital 
membrane, flanked on each side by outer genital swellings and inner urethral folds. The male 
embryo urogenital system develops during weeks 8 to 14 following ovulation.
27
 Masculinization 
of the external genitalia occurs under the influence of testosterone in response to a surge of 
luteinizing hormone from the pituitary gland and is signified by an increase in the distance 
between the anus and genital structures, followed by elongation of the genital tubercle which will 
become the penile shaft and glans, formation of the penile urethra from the urethral groove, and 
development of the prepuce.
29
 The scrotum is formed when the genital swellings, also known as 
the labioscrotal folds, migrate caudally and fuse.
27
 Fusion of the medial edges of the endodermal 
urethral folds forms the penile urethra 
29
 and creates an epithelial seam that is subsequently 
reabsorbed.
27
 Fusion of the ectodermal edges of the urethral groove forms the median raphe.
29
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Two possible mechanisms have been proposed for the development of the distal, or 
glanular, urethra.
29
 The standard theory is that the distal portion of the urethra develops as an 
ingrowth from the tip of the penis until it joins the proximal tubular urethra; however, recent 
evidence suggests that the entire urethra is formed from base to tip by continuous extension and 
fusion of the endodermal urethral groove.
27
 
 Proper formation of the urethral groove, urethral folds, and fusion of the folds with seam 
formation and seam removal is required in the development of a normal penile urethra with a 
meatus at the tip of the glans. Hypospadias results from failed seam formation during the fusion 
of the urethral folds and the final position of the urethral meatus is dictated by the site of 
failure.
27
  
2.3 Hypospadias Epidemiology 
 Hypospadias is one of the most common birth defects in the United States. It is estimated 
that each year hypospadias occurs in approximately 1 in 250 newborns or about 1 out of 125 live 
male births.
25,30
 Non-Hispanic whites appear to be at a higher risk than other racial-ethnic groups 
for most subgroups of hypospadias,
27
 with hypospadias occurring at a reported incidence of 0.3% 
to 0.8% for white male live births and 0.05% to 0.4% for minority male live births.
31
 
 In previous years there were reports of increasing rates of hypospadias in industrialized 
countries. Congenital anomaly surveillance systems in Norway, Sweden, Denmark, England, and 
Hungary reported upward trends in the birth prevalence of hypospadias in the 1970s and 1980s. 
In 1997, Paulozzi and colleagues published a study examining data from the Metropolitan 
Atlanta Congenital Defects Program (MACDP) and the nationwide Birth Defects Monitoring 
Program (BDMP), to determine whether an increase in the birth prevalence of hypospadias had 
occurred in the United States. Data from both surveillance systems showed an approximate 
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doubling of hypospadias rates in the 1970s and 1980s, compared with immediately preceding 
decades.
30
  
The reason that the hypospadias rates doubled over previous years is not known, but 
recent evidence suggests that the birth prevalence of hypospadias has stabilized in recent years.
27
 
A retrospective review of data from the New York State Congenital Malformations Registry, 
from 1992-2005, found no statistical change in hypospadias rates in New York State.
32
 And no 
increase in prevalence of hypospadias was found in California in an analysis of data from the 
California Birth Defects Monitoring Program (CBDMP) from 1989-1997.
33
 Similarly, a 
retrospective review of discharge records between 1990 and 1998 from 15 military treatment 
facilities reported no increase in overall incidence of hypospadias.
31
    
2.4 Etiology and Risk Factors for Hypospadias 
 Hypospadias appears to be governed by a wide range of known and unknown endocrine, 
genetic, and environmental factors, however in the vast majority of individual cases, the specific 
etiology of hypospadias cannot be determined.
27
 
 Androgens are essential for normal urogenital development in males. Synthesized by the 
Leydig cells, androgenic steroids are first seen just before the onset of androgen-induced genital 
differentiation.
34
 Human chorionic gonadotropin (hCG) stimulates the Leydig cells of the fetal 
testes to produce testosterone, which is then converted to the more active dihydrotestosterone 
(DHT) by the enzyme 5-α reductase type II.27 Normal urethral closure is dependent on 
conversion of testosterone to DHT and proper androgen receptor signaling.
35
 Even a partial 
deficiency of 5-α reductase type II can result in inadequate levels of DHT.27 Hypospadias 
anatomy appears to be consistent with incomplete embryologic development due to abnormal 
androgen production by the fetal testis, limited androgen sensitivity in target tissues of the 
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developing genitalia, or premature cessation of androgenic stimulation due to early atrophy of 
the Leydig cells of the testes.
21
 Fifty percent of boys with severe forms of hypospadias have 
defects in one or more of the enzymes required for the biosynthesis of testosterone and 9.7% of 
boys with isolated hypospadias have been found to have 5-α reductase type II mutations.27 
However, despite these finding, less than 5% of all patients with hypospadias can be explained 
by androgen metabolism abnormalities such as 5-α reductase type II deficiency, androgen 
receptor defects, or genetic defects, implying that other factors are responsible for 
hypospadias.
25,28
 
Hypospadias is believed to have a complex genetic background in which gene expression 
acts along with environmental factors, suggesting a possible mechanism for the well-recognized 
familial tendency.
21,27
 The exact mode of inheritance has not been well defined.
36
 Familial 
clustering is seen in 4-25% of cases and the more severe the malformation of the index patient, 
the higher the recurrence risk for the next male sibling.
37
 About 9% of fathers and 14% of 
brothers of boys with hypospadias have the condition, as well.
27
 An increased incidence of 
hypospadias has also been seen in both monozygotic and dizygotic twins.
37
 
 Birth weight has also been found to be significantly associated with hypospadias when 
genetic effects are controlled.
38
 Several epidemiological investigations from different countries 
have found that low birth weight is associated with approximately twice the risk of 
hypospadias.
39
 In a study by Fredell and colleagues, published in 1998, results showed that in 16 
out of 18 discordant monozygotic pairs, the twin with the lowest birth weight had hypospadias. 
The authors surmised that because hypospadias manifested or was worse in the smaller twin of 
discordant pairs that it suggests placental inadequacy to provide nutrients for both fetuses or 
insufficient hCG to meet the demand of two pairs of male gonads, which would affect the 
10 
 
smaller and more sensitive of the two male fetuses.
38
 Additionally, hypospadias is 10 times more 
common among small-for-gestational-age infants in neonatal intensive care than in the general 
neonatal population
27
 Hypospadias is significantly more common in infants with uniformly poor 
intrauterine growth (<10
th
 percentiles), as measured by birth weight, length, or head 
circumference.
40
 
 There also appears to be an association between some maternal reproductive and 
demographic characteristics and hypospadias risk. Carmichael et al. found that maternal 
primiparity, age 35 years or older, and a pre-pregnancy BMI greater than 26 are associated with 
increased risk of hypospadias among offspring, especially when present in combination. It has 
been hypothesized that increased maternal estrogen levels may be associated with increased 
hypospadias risk and that maternal age, parity, and BMI may be predictive of the production and 
action of maternal estrogens.
35
 
 In addition, sub-fertility, both maternal and paternal, has been proposed to contribute to 
higher risk of hypospadias.
25,35
 Low sperm motility and abnormal sperm morphology have been 
found to a greater degree in fathers of boys with hypospadias and it is speculated that 
hypospadias in some boys after intracytoplasmic sperm injection (ICSI) might reflect inheritance 
of the mutant genes that caused the paternal subfertility.
27
 Likewise, assisted reproductive 
technology, such as in vitro fertilization (IVF), may contribute to the higher prevalence of 
hypospadias through a higher rate of twinning.
39
  
 Finally, there is growing concern that exposure to endocrine disruptors might be 
contributing to declining reproductive health in humans, particularly, males.
21,24,25,27–29
 Endocrine 
disruptors are hormonally active agents in the environment that are synthetic or natural 
substances that can interfere with hormone systems by mimicking, blocking, or otherwise 
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altering the normal action of hormones during critical periods of embryonic or fetal 
development.
27
 Humans and wild animals are constantly exposed to endocrine disruptors through 
insecticides used in crop production, natural plant estrogens, byproducts of plastic production, 
internal plastic coating used in the canned food industry inside metal cans, and 
pharmaceuticals.
29
 It is theorized that exposure to anti-androgens, which are endocrine disruptors 
that inhibit androgen binding, androgen synthesis, and androgen-induced gene expression, during 
development of the urogenital tract can impede normal male differentiation and result in 
hypospadias.
27
                  
2.5 Medication Use during Pregnancy and Risk of Hypospadias  
 Statistically significant positive associations have been observed between maternal use of 
oral nystatin, valproic acid, progestins, proton pump inhibitors (PPIs), and steroids during 
pregnancy and hypospadias.
16–19
  
In the population-based data set of the Hungarian Case-Control Surveillance of 
Congenital Abnormalities between 1980 and 1996, a teratogenic potential of nystatin was seen in 
the hypospadias case group for exposures during the critical period for the development of 
hypospadias. Results from the study indicated a higher maternal nystatin use during the third and 
fourth months of gestation among hypospadias cases, resulting in an adjusted odds ratio (aOR) of 
4.0 with a 95% confidence interval (CI) of 1.1-14.2.
17
 
 Hypospadias is one of the most frequently described genital anomalies observed in 
infants prenatally exposed to valproic acid. Results from a case-control study, by Rodriguez-
Pinilla et al., using data derived from the Spanish Collaborative Study of Congenital 
Malformations showed that the adjusted risk of hypospadias in infants prenatally exposed to 
valproic acid was 5.71 (95% CI 1.78-18.36, p=0.003).
18
 Also, in a study using data from the 
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National Birth Defects Prevention Study (NBDPS) by Werler and colleagues, evaluating the use 
of specific antiepileptic drugs in pregnancy in relation to specific birth defects, an elevated 
adjusted odds ratio for hypospadias was observed for infants born to valproic acid-exposed 
mothers, although the lower confidence bounds were below 1.0 (aOR 2.4; 95% CI 0.62-9.0).
41
 
 In light of previous studies that have suggested that maternal intake of progestins during 
early pregnancy may be associated with an increased risk of hypospadias, Carmichael and 
colleagues examined the risk of hypospadias associated with periconceptional progestin intake 
using data from NBDPS. Case mothers in the study were 3.7 times more likely to be exposed to 
progestins during early pregnancy than control mothers (95% CI 2.3-6.0).
16
 
 Anderka et al. used NBDPS data to examine whether nausea and vomiting due to 
pregnancy or its treatment (i.e. antihistamine antiemetics, other antihistamines, prokinetics, 
5HT3 antagonists, Emetrol (coke syrup), antacids, H2 blockers, proton pump inhibitors, 
pyridoxine, steroids, and herbal or natural products) was associated with the most common non-
cardiac defects in the NBDPS, including hypospadias, compared with randomly selected non-
malformed live births. Regarding treatments for nausea and vomiting due to pregnancy, the study 
found statistically significant positive associations with first-trimester use of PPIs and 
hypospadias (aOR 4.36, 95% CI 1.21-15.81) and steroids and hypospadias (aOR 2.87, 95% CI 
1.03-7.97).
19
 
 In the current analysis, recently collected data from the National Birth Defects Prevention 
Study (NBDPS) was used to examine the relationship between maternal medication use during 
the periconceptional period and early pregnancy and the risk of severe hypospadias in male 
infants.     
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Chapter III  
METHODOLOGY 
3.1 Data Source and Study Population 
The data used in this analysis were collected as part of the National Birth Defects 
Prevention Study (NBDPS). NBDPS is an ongoing, multi-site, population-based, case-control 
study which seeks to identify risk factors associated with more than 30 selected categories of 
major birth defects. The study is the result of a collaborative effort by the Centers for Birth 
Defects Research and Prevention (CBDRP), coordinated by the Centers for Disease Control and 
Prevention (CDC), and is the largest population-based U.S. study looking at the risk factors for 
and potential causes of birth defects. Annually, each study site contributes maternal interviews of 
approximately 300 case subjects with any of the selected birth defects and 100 liveborn control 
subjects without birth defects. Case infants are identified through population-based surveillance 
and all case records are reviewed by a clinical geneticist to ensure they meet the case definition, 
while control infants are randomly selected from either birth hospital or birth certificate records 
from the same geographic area and time period as the cases. Data have been contributed by 10 
states (Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North 
Carolina, Texas, and Utah), all of which use a standardized protocol that was developed by the 
NBDPS collaborative. The study design was approved by the institutional review boards of the 
participating study centers and by the CDC, and study participants provided informed consent. 
Detailed study methods
42
 and description of case classification methods
43
 have been published 
elsewhere.  
 NBDPS uses computer-assisted telephone interviews to collect information from women. 
Mothers were contacted by telephone and interviewed 6 weeks to 24 months after their estimated 
date of delivery (EDD). The interviews take about one hour and are conducted in English or 
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Spanish. The interview covers a wide range of exposures, selected based on hypotheses about 
what causes birth defects and were broadly defined to include maternal health and reproductive 
characteristics, environmental exposures, and nutritional and behavioral factors. 
 NBDPS included only cases of second- or third-degree hypospadias, which was defined 
as the urethral opening at the penile shaft, scrotum, or perineum and included the modified 
British Pediatric Association codes 752.606, 752.607, 752.626, and 752.627. A clinical geneticist 
at each study center reviewed medical record information with anatomic descriptions or 
diagrams by pediatricians, urologists, geneticists, pathologists, or other health care providers to 
determine whether to include or exclude cases in the NBDPS database. A clinical geneticist 
further classified eligible cases of hypospadias into isolated, if there was no concurrent major 
anomaly or only a minor anomaly, or multiple, if there was at least one unrelated accompanying 
major anomaly in another organ system.  
This study included data on deliveries with estimated dates of delivery (EDD) between 
October 1997 and December 2007. The analysis is restricted to all male controls and isolated 
hypospadias cases, as isolated cases represented 90.6% of all hypospadias cases and are 
considered a more etiologically homogeneous group of defects than those defects associated with 
additional anomalies.
43–46
  
We considered maternal medication exposures from 1 month before to 4 months after 
conception, with the date of conception estimated by subtracting 266 days from the EDD. This 
window of exposure was defined to capture the periconceptional period and weeks 8-14 
postconception, the latter of which is the period of development for the male embryo urogenital 
system.
27
 Medications were broadly defined to include reported use of any prescription, over-the-
counter, or herbal drug. The Slone Epidemiology Center Drug Dictionary was used by a central 
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coding facility to assign codes for each reported product and for the components of which these 
products were comprised. In this analysis only medication components for which there were at 
least 5 exposed cases were assessed. Topicals, vitamins, minerals, and not otherwise specified 
(NOS) components were excluded from the analysis. Equivalent medications, such as 
amoxicillin and amoxicillin trihydrate, were combined.    
3.2 Statistical Analysis  
The analysis assessed whether medication exposures differed among mothers of isolated 
hypospadias cases and mothers of male controls. Crude odds ratios (ORs) were estimated for 
each medication component exposure. Potential confounders for the adjusted analyses were 
selected a priori based on previous knowledge, and were maternal age (<35 yr/≥35 yr), 
race/ethnicity (Non-Hispanic White/Non-Hispanic Black/Hispanic/Other), education (<high 
school/high school/1-3 yr of college/≥4 yr of college), pre-pregnancy body mass index (BMI) 
(underweight/normal/overweight/obese; defined below), parity (0 births/1 birth/≥2 births), 
maternal sub-fertility (any fertility-related treatments and procedures/none), study site, and year 
of due date in two year increments. The maternal sub-fertility variable was based on a positive 
response to any of the following 3 questions: 1) “Did you have any surgical procedures [to help 
you become pregnant]?”; 2) “In the 2 months before you became pregnant with [baby’s name], 
did you take any medications to help you become pregnant?”; and 3) “Did you have any other 
procedures to help you become pregnant?” Pre-pregnancy BMI was based on standard BMI 
categories, with <18.5 for underweight, 18.5-24.9 for normal weight, 25.0-29.9 for overweight, 
and ≥30.0 for obese.47 Adjusted odds ratios (aORs) and their corresponding 95% confidence 
intervals (CIs) were estimated using multivariable logistic regression. Sub-analyses were 
performed on associations for which the lower bound of the 95% CI was ≥0.95 for crude or 
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adjusted OR estimates >1 or the upper bound was ≤1.05 for crude or adjusted OR estimates <1 in 
the primary analyses (i.e. at least borderline statistically significant). Separate sub-analyses were 
conducted in which infants with a positive family history were excluded, low birth weight infants 
and multiple births were excluded, and mothers reporting illicit drug use were excluded, to 
evaluate whether these factors would make a difference in results. Data management and 
analysis were performed using the Statistical Package for the Social Sciences (SPSS) software, 
version 17.0. Throughout all analyses performed, a P-value less than 0.05 was considered 
statistically significant.    
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Chapter IV 
RESULTS 
 Among infants in the NBDPS with an EDD from October 1997 through December 2007, 
1,697 cases of second- or third-degree hypospadias were identified. Of the cases identified, 1,537 
(90.6%) infants had isolated hypospadias. The control group consisted of 4,314 non-malformed 
male infants. One hundred and ninety-five medication components were identified for which 
there were at least 5 exposed cases. Of the 195 medication components, 104 components 
(topicals; vitamins; minerals; NOS components) were excluded and 2 equivalent component 
pairs (amoxicillin and amoxicillin trihydrate; albuterol and albuterol sulfate) were combined. 
Thus, 89 medication components were assessed for their association with hypospadias.  
 Table 1 gives the maternal and infant characteristics of the hypospadias cases and 
controls. Case mothers were significantly more likely than control mothers to be Non-Hispanic 
White, 35 years of age or older at delivery, to have 4 or more years of college, to be obese, to 
have an annual family income >$50,000, to have used alcohol during the periconceptional 
period, to have used folic acid during the periconceptional period, to be nulliparous, to have 
given birth to multiples, and to have used treatments or procedures for sub-fertility. Control 
mothers were significantly more likely than case mothers to be Hispanic and to have used illicit 
drugs during the periconceptional period. Case infants were significantly more likely than 
control infants to be delivered preterm, to have a low birth weight, and to have a family history 
of hypospadias. There were also differences in the distribution of cases and controls by study site 
and EDD.           
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Table 1: Descriptive Characteristics of Mothers of Case and Control Infants: National Birth 
Defects Prevention Study, October 1997 to December 2007 
 
Characteristic Isolated  
Hypospadias Cases  
(n= 1537) 
Controls  
(n= 4314) 
P Value
a 
 N (%)  
Race/Ethnicity   < .001 
     Non-Hispanic White 1,125 (73.2%) 2,513 (58.3%)  
     Non-Hispanic Black 194 (12.6%) 479 (11.1%)  
     Hispanic 122 (7.9%) 1,019 (23.6%)  
     Other 95 (6.2%) 301 (7.0%)  
     Missing 1 2  
    
Age at Delivery   < .001 
     <35 yr 1,224 (79.6%) 3,721 (86.3%)  
     ≥35 yr 313/ (20.4%) 593 (13.7%)  
    
Education   < .001 
     < High School 117 (7.7%) 756 (17.8%)  
     High School 295 (19.5%) 1,047 (24.7%)  
     1-3 yr of College 420 (27.8%) 1,125 (26.6%)  
     ≥4 yr of College 680 (45.0%) 1,309 (30.9%)  
     Missing 25 77  
    
Pre-pregnancy Body Mass 
Index (kg/m
3
) 
  .003 
     Underweight (<18.5) 80 (5.2%) 238 (5.5%)  
     Normal (18.5-24.9) 824 (53.6%) 2,272 (52.7%)  
     Overweight (25.0-29.9) 341 (22.2%) 938 (21.7%)  
     Obese (≥30.0) 257 (16.7%) 674 (15.6%)  
    
Annual Family Income   < .001 
     <$10,000 149 (10.0%) 793 (19.6%)  
     $10,000-$50,000 533 (35.7%) 1764 (43.5%)  
     >$50,000 756 (50.7%) 1324 (32.7%)  
     Missing 45 259  
    
Cigarette Smoking
b   .42 
     Yes 265 (17.2%) 809 (18.8%)  
     No 1248 (81.2%) 3,441 (79.8%)  
    
Alcohol Use
b   < .001 
     Yes 656 (42.7%) 1583 (36.7%)  
     No 847 (55.1%) 2644 (61.3%)  
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Maternal Illicit Drug Use
b   .02 
     Yes 50 (3.3%) 202 (4.7%)  
     No 1487 (96.7%) 4,112 (95.3%)  
    
Folic Acid Use
c
   .002 
     Yes 1,400 (91.6%) 3,813 (88.7%)  
     No 129 (8.4%) 485 (11.3%)  
     Missing 8 16  
    
Parity    < .001 
     0 births 816 (53.3%) 1,729 (40.2%)  
     1 birth 454 (29.7%) 1,419 (33.0%)  
     ≥2 births 260 (17.0%) 1,157 (26.9%)  
     Missing 7 9  
    
Plurality   < .001 
     Singleton 1,416 (92.2%) 4,182 (97.1%)  
     Multiple 119 (7.8%) 123 (2.9%)  
     Missing 2 9  
    
Maternal Subfertility 
Treatments and Procedures 
  < .001 
     None 1,373 (89.7%) 4,121 (95.8%)  
     Any 157 (10.3%) 180 (4.2%)  
     Missing 7 13  
    
Study Site   < .001 
     Arkansas 209 (13.6%) 539 (12.5%)  
     California 68 (4.4%) 523 (12.1%)  
     Georgia 212 (13.8%) 459 (10.6%)  
     Iowa 84 (5.5%) 473 (11.0%)  
     Massachusetts 335 (21.8%) 534 (12.4%)  
     New Jersey 286 (18.6%) 258 (6.0%)  
     New York 92 (6.0%) 383 (8.9%)  
     North Carolina 124 (8.1%) 312 (7.2%)  
     Texas 28 (1.8%) 530 (12.3%)  
     Utah 99 (6.4%) 303 (7.0%)  
    
Year of Due Date   .01 
     1997-1999 280 (18.3%) 839 (19.5%)  
     2000-2001 348 (22.7%) 853 (19.8%)  
     2002-2003 250 (16.3%) 855 (19.8%)  
     2004-2005 346 (22.6%) 894 (20.7%)  
     2006-2007 310 (20.2%) 872 (20.2%)  
     Missing 3 1  
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Infant Characteristics 
    
Preterm Birth  
(<37 weeks) 
  < .001 
     Yes 375 (24.7%) 407 (9.4%)  
     No 1141 (75.3%) 3,906 (90.6%)  
     Missing 21 1  
    
Low Birthweight  
(<2,500 g) 
  < .001 
     Yes 380 (25.0%) 241 (5.6%)  
     No 1,137 (75.0%) 4,055 (94.4%)  
     Missing 20 18  
    
Family History of 
Hypospadias
d 
  < .001 
     Yes  74/1537 (4.8%) 9/4314 (0.2%)  
     No 1463/1537 (95.2%) 4305/4314 (99.8%)  
    
a
 P values were calculated by Pearson’s chi-square test. 
b 
Any time 1 month preconception through month 3 postconception. 
c
 Any time 1 month preconception through month 4 postconception. 
d
 Family history of hypospadias in a first degree relative (mother, father, full sibling) or previous 
pregnancy. 
 
 
Unadjusted (OR) and adjusted (aOR) odds ratios were estimated for 89 medication 
exposures (Table 2). Statistically significant positive associations with isolated hypospadias were 
observed  for maternal use of phenylpropanolamine HCl (OR 2.82; 95% CI 1.17, 6.80), labetalol 
(OR 4.24; 95% CI 1.51, 11.93), acetaminophen (OR 1.19; 95% CI 1.05, 1.35), ibuprofen (OR 
1.36; 95% CI 1.19, 1.55), aspirin (OR 1.42; 95% CI 1.10, 1.84), butalbital (OR 2.82; 95% CI 
1.06, 7.53), lutein (OR 1.48; 95% CI 1.06, 2.07), lycopene (OR 1.65; 95% CI 1.00, 2.71), barley 
grass (OR 2.82; 95% CI 1.17, 6.80), progesterone (OR 2.62; 95% CI 1.97, 3.48), iodine (OR 
1.34; 95% CI 1.16, 1.54), and levothyroxine sodium (OR 1.81; 95% CI 1.24, 2.64), in the 
unadjusted analysis.  
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 In analyses adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, 
parity, maternal sub-fertility, study site, and year of due date, statistically significant associations 
with isolated hypospadias were observed only for maternal use of phenylpropanolamine HCl 
(aOR 2.68; 95% CI 1.06, 6.80), ibuprofen (aOR 1.16; 95% CI 1.00, 1.34), and cephalexin (aOR 
3.06; 95% CI 1.02, 9.18) (Table 2).  
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Table 2: Association of Isolated Hypospadias with Maternal Medication Use,
a
 National Birth 
Defects Prevention Study, October 1997 to December 2007. 
 
Medication Exposure Exposed 
Cases 
Exposed 
Controls 
OR (95% CI) Adjusted OR
b
  
(95% CI) 
Antihistamines, First 
Generation 
    
     Diphenhydramine HCl 38 98 1.09 (0.75, 1.60) 1.01 (0.67, 1.51) 
     Doxylamine Succinate 27 68 1.12 (0.71, 1.75) 0.98 (0.61, 1.60) 
     Chlorpheniramine  
     Maleate 
37 78 1.35 (0.91, 2.00) 1.35 (0.88, 2.09) 
     Promethazine 8 23 0.98 (0.44, 2.19) 0.97 (0.40, 2.36) 
     Promethazine HCl 38 126 0.84 (0.58, 1.22) 0.77 (0.52, 1.13) 
Antihistamines, Second 
Generation 
    
     Cetirizine HCl 21 46 1.29 (0.77, 2.17) 0.99 (0.57, 1.71) 
     Fexofenadine HCl 22 39 1.60 (0.94, 2.70) 1.13 (0.65, 1.97) 
     Loratadine 46 98 1.33 (0.93, 1.90) 1.11 (0.76, 1.62) 
Antibiotics     
     Cephalexin 6 8 2.11 (0.73, 6.10) 3.06 (1.02, 9.18) 
     Azithromycin 19 70 0.76 (0.46, 1.27) 0.61 (0.35, 1.05) 
     Amoxicillin Trihydrate 85 233 1.03 (0.80, 1.33) 1.01 (0.77, 1.33) 
     Sulfamethoxazole 15 38 1.11 (0.61, 2.03) 1.06 (0.55, 2.02) 
Antibiotics, Urinary     
     Nitrofurantoin 28 67 1.18 (0.76, 1.84) 1.27 (0.79, 2.06) 
     Nitrofurantoin  
     Monohydrate 
25 58 1.22 (0.76, 1.95) 1.24 (0.74, 2.08) 
     Trimethoprim 15 38 1.11 (0.61, 2.03) 1.06 (0.55, 2.02) 
Alpha/Beta Agonists     
     Ephedra 8 28 0.80 (0.37, 1.76) 1.03 (0.45, 2.35) 
     Phenylpropanolamine  
     HCl 
10 10 2.82 (1.17, 6.80) 2.68 (1.06, 6.80) 
     Pseudoephedrine HCl 144 380 1.07 (0.88, 1.31) 0.92 (0.73, 1.14) 
     Pseudoephedrine Sulfate 6 13 1.30 (0.49, 3.43) 1.18 (0.42, 3.33) 
Alpha-Adrenergic Agonists     
     Phenylephrine HCl 7 13 1.52 (0.60, 3.81) 1.70 (0.64, 4.52) 
Beta2-Adrenergic Agonists     
     Albuterol Sulfate 49 122 1.13 (0.81, 1.59) 1.13 (0.78, 1.62) 
     Salmeterol Xinafoate 12 20 1.69 (0.83, 3.47) 1.66 (0.77, 3.62) 
Antilipemics     
     Niacin 158 432 1.03 (0.85, 1.25) 0.85 (0.69, 1.05) 
Cardiovascular Agents     
     Labetalol 9 6 4.24 (1.51, 11.93) 2.58 (0.86, 7.74) 
     Atenolol 5 10 1.41 (0.48, 4.12) 1.01 (0.31, 3.27) 
     Methyldopa 9 21 1.21 (0.55, 2.64) 1.05 (.44, 2.47) 
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Analgesics 
     Acetaminophen 956 2514 1.19 (1.05, 1.35) 0.96 (0.84, 1.10) 
     Ibuprofen 423 945 1.36 (1.19, 1.55) 1.16 (1.00, 1.34) 
     Naproxen Sodium  76 176 1.23 (0.93, 1.62) 0.99 (0.74, 1.33) 
     Aspirin 93 187 1.42 (1.10, 1.84) 1.25 (0.94, 1.66) 
     Codeine Phosphate 14 39 1.01 (0.55, 1.87) 0.86 (0.45, 1.68) 
     Meperidine HCl 8 21 1.07 (0.47, 2.42) 1.05 (0.45, 2.45) 
     Oxycodone HCl 11 17 1.83 (0.85, 3.91) 1.13 (0.50, 2.57) 
CNS Stimulants     
     Caffeine 27 52 1.47 (0.92, 2.35) 1.08 (0.66, 1.78) 
Barbiturates     
     Butalbital 8 8 2.82 (1.06, 7.53) 2.07 (0.74, 5.77) 
Antidepressants     
     Bupropion HCl 12 26 1.30 (0.65, 2.58) 1.32 (0.65, 2.70) 
     Venlafaxine 9 11 2.31 (0.96, 5.58) 2.38 (0.95, 5.96) 
     Fluoxetine HCl  13 42 0.87 (0.47, 1.63) 0.88 (0.45, 1.74) 
     Paroxetine HCl 9 29 0.87 (0.41, 1.85) 1.00 (0.45, 2.20) 
     Sertraline HCl 22 48 1.29 (0.78, 2.15) 1.22 (0.71, 2.10) 
GI, Antiemetics     
     Ondansetron HCl 23 45 1.44 (0.87, 2.39) 0.97 (0.57, 1.65) 
GI, Antiflatulants     
     Simethicone 12 33 1.02 (0.53, 1.99) 0.68 (0.33, 1.39) 
GI, Antiulcer Agents and 
Acid Suppressants 
    
     Ranitidine HCl 11 27 1.15 (0.57, 2.32) 0.91 (0.43, 1.92) 
     Lansoprazole 6 6 2.82 (0.91, 8.76) 2.81 (0.80, 9.83) 
     Omeprazole 5 5 2.82 (0.82, 9.75) 2.87 (0.73, 11.29) 
GI, Cathartics and 
Laxatives 
    
     Docusate Sodium 190 516 1.04 (0.87, 1.24) 0.94 (0.78, 1.14) 
GI, Digestants     
     Betaine HCl 5 20 0.70 (0.26, 1.87) 0.65 (0.23, 1.80) 
GI, Prokinetic Agents     
     Metoclopramide HCl 9 17 1.49 (0.66, 3.35) 1.06 (0.45, 2.49) 
Herbals     
     Bioflavonoid Compound 19 47 1.14 (0.67, 1.95) 0.84 (0.47, 1.48) 
     Hesperidin Complex 5 6 2.35 (0.72, 7.70) 2.06 (0.60, 7.09) 
     Rutin 9 30 0.84 (0.40, 1.78) 0.66 (0.30, 1.42) 
     Spirulina 11 26 1.19 (0.59, 2.42) 0.87 (0.41, 1.83) 
     Lutein 54 104 1.48 (1.06, 2.07) 1.16 (0.81, 1.66) 
     Lycopene 25 43 1.65 (1.00, 2.71) 1.31 (0.77, 2.22) 
     Alfalfa 7 22 0.89 (0.38, 2.10) 0.67 (0.27, 1.62) 
     Allium Sativum, Herb 9 25 1.01 (0.47, 2.17) 0.92 (0.41, 2.07) 
     Angelica Polymorpha 8 22 1.02 (0.45, 2.30) 0.78 (0.33, 1.84) 
     Barley Grass 10 10 2.82 (1.17, 6.80) 2.13 (0.84, 5.38) 
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     Bee Pollen 11 29 1.07 (0.53, 2.14) 1.05 (0.50, 2.17) 
     Cranberry Concentrate 6 9 1.88 (0.67, 5.29) 1.58 (0.55, 4.58) 
     Echinacea 11 22 1.41 (0.68, 2.91) 1.23 (0.57, 2.65) 
     Ginger 17 43 1.11 (0.63, 1.96) 1.02 (0.56, 1.86) 
     Ginkgo Biloba Extract 8 13 1.73 (0.72, 4.19) 1.60 (0.59, 4.36) 
     Ginseng 10 20 1.41 (0.66, 3.02) 1.42 (0.64, 3.19) 
     Herbal Tea 17 35 1.37 (0.77, 2.45) 1.84 (0.96, 3.52) 
     Hydrastis Canadensis 6 12 1.41 (0.53, 3.76) 1.61 (0.57, 4.53) 
     Hypericum Perforatum 5 6 2.35 (0.72, 7.71) 1.70 (0.49, 5.87) 
     Peppermint 5 13 1.08 (0.39, 3.04) 0.75 (0.25, 2.25) 
     Raspberry Leaf 18 33 1.54 (0.87, 2.74) 0.94 (0.51, 1.75) 
     Sarsaparilla Root 5 8 1.76 (0.58, 5.39) 2.25 (0.67, 7.57) 
     Siberian Ginseng 5 13 1.08 (0.39, 3.04) 1.17 (0.39, 3.51) 
     Thea Sinesis 12 32 1.06 (0.54, 2.05) 0.85 (0.42, 1.75) 
     Vitis Vinifera 8 10 2.26 (0.89, 5.73) 1.94 (0.70, 5.34) 
     Glucosamine 6 0 --- --- 
     Royal Jelly 10 31 0.91 (0.44, 1.85) 0.81 (0.38, 1.72) 
     Lactobacillus  
     Acidophilus 
5 14 1.00 (0.36, 2.79) 0.70 (0.24, 2.02) 
Steroids, Glucocorticoids     
     Budesonide 6 8 2.11 (0.73, 6.10) 1.23 (0.41, 3.73) 
     Fluticasone Propionate 21 39 1.52 (0.89, 2.59) 1.13 (0.64, 2.01) 
     Prednisone 5 15 0.94 (0.34, 2.59) 0.59 (0.20, 1.72) 
     Triamcinolone Acetonide 5 8 1.76 (0.58, 5.39) 1.88 (0.57, 6.22) 
Antidiabetic Agents, 
Biguanide 
    
     Metformin HCl 7 12 1.64 (0.65, 4.18) 0.92 (0.34, 2.52) 
Progestins     
     Progesterone 93 104 2.62 (1.97, 3.48) 1.25 (0.89, 1.76) 
     Progesterone Gel 8 1 --- --- 
Thyroid and Antithyroid 
Agents 
    
     Iodine 363 813 1.34 (1.16, 1.54) 1.17 (1.00, 1.37) 
     Levothyroxine Sodium 45 71 1.81 (1.24, 2.64) 1.33 (0.88, 2.01) 
     Potassium Iodide 67 176 1.07 (0.81, 1.43) 0.81 (0.59, 1.11) 
Respiratory Agents     
     Dextromethorphan HBR 50 113 1.25 (0.89, 1.76) 1.02 (0.71, 1.47) 
     Guaifenesin 41 120 0.96 (0.67, 1.37) 0.82 (0.55, 1.21) 
Miscellaneous Therapeutic 
Agents 
    
     Potassium Clavulanate 8 18 1.25 (0.54-2.88) 1.16 (0.48, 2.79) 
     
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index. 
a
 Medication exposure is reported for the period from 1 month before to 4 months after 
conception.  
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b 
Odds ratios are adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, parity, 
sub-fertility, study site, and year of due date. 
--- Odds ratios were not estimated for medication components with fewer than 5 exposed 
controls.  
  
 
Of the 89 medication components considered in the primary analyses, 17 had at least 
borderline statistically significant crude or adjusted OR estimates for their association with 
isolated hypospadias. Overall, the results of sub-analyses in which infants with a positive family 
history of hypospadias were excluded did not change adjusted OR estimates appreciably (Table 
3). Associations of isolated hypospadias with cephalexin (aOR 3.29; 95% CI 1.10, 9.87) and 
venlafaxine (aOR 2.52; 95% CI 1.01, 6.31) were stronger when infants with a positive family 
history were excluded. The association of phenylpropanolamine HCl with isolated hypospadias 
was slightly attenuated when infants with a positive family history were excluded (aOR 2.58; 
95% CI 0.99, 6.73).  
 
Table 3: Association of Isolated Hypospadias with Maternal Use of Specific Medications, 
Excluding Infants with a Positive Family History, National Birth Defects Prevention Study, 
October 1997 to December 2007.
a,b
 
 
Medication Exposure Exposed 
Cases  
Exposed 
Controls 
aOR
c
 (95% CI) 
Sub-Analysis 
aOR (95% CI) 
Primary Analysis 
     
Cephalexin 6 8 3.29 (1.10, 9.87) 3.06 (1.02, 9.18) 
Azithromycin 19 70 0.65 (0.37, 1.11) 0.61 (0.35, 1.05) 
Phenylpropanolamine 
HCl 
9 10 2.58 (0.99, 6.73) 2.68 (1.06, 6.80) 
Niacin 143 430 0.81 (0.65, 1.01) 0.85 (0.69, 1.05) 
Labetalol 9 6 2.65 (0.88, 7.96) 2.58 (0.86, 7.74) 
Acetaminophen 895 2507 0.93 (0.81, 1.07) 0.96 (0.84, 1.10) 
Ibuprofen 403 942 1.16 (1.00, 1.35) 1.16 (1.00, 1.34) 
Aspirin 90 186 1.27 (0.95, 1.68) 1.25 (0.94, 1.66) 
Butalbital 8 8 2.20 (0.79, 6.13) 2.07 (0.74, 5.77) 
Venlafaxine 9 11 2.52 (1.01, 6.31) 2.38 (0.95, 5.96) 
Lutein 50 104 1.12 (0.77, 1.62) 1.16 (0.81, 1.66) 
Lycopene 23 43 1.27 (0.74, 2.19) 1.31 (0.77, 2.22) 
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Barley Grass 8 10 1.65 (0.62, 4.41) 2.13 (0.84, 5.38) 
Herbal Tea 16 35 1.81 (0.94, 3.51) 1.84 (0.96, 3.52) 
Progesterone 89 104 1.26 (0.90, 1.78) 1.25 (0.89, 1.76) 
Iodine 334 813 1.12 (0.95, 1.31) 1.17 (1.00, 1.37) 
Levothyroxine Sodium 43 71 1.34 (0.88, 2.03) 1.33 (0.88, 2.01) 
     
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval 
a
 Medication exposure is reported for the period from 1 month before to 4 months after 
conception. 
b
 Family history of hypospadias in a first degree relative (mother, father, full sibling) or previous 
pregnancy. 
c
 Odds ratios were adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, 
parity, sub-fertility, study site, and year of due date. 
 
 Sub-analyses in which low birth weight infants and multiple births were excluded 
demonstrated attenuated results relative to the primary analysis for several of the medications, 
including cephalexin (aOR 1.37; 0.27, 6.95) (Table 4). However, in this sub-analysis, the 
association of isolated hypospadias was much stronger with maternal use of venlafaxine (aOR 
3.67; 95% CI 1.39, 9.70) and slightly stronger with phenylpropanolamine HCl, although only 
marginally significant (aOR 2.83; 95% CI 0.98, 8.16).    
 
 
Table 4: Association of Isolated Hypospadias with Maternal Use of Specific Medications, 
Excluding Low Birth Weight Infants and Multiple Births, National Birth Defects Prevention 
Study, October 1997 to December 2007.
a
  
 
Medication Exposure Exposed 
Cases  
Exposed 
Controls 
aOR
b
 (95% CI) 
Sub-Analysis 
aOR (95% CI) 
Primary Analysis 
     
Cephalexin 2 7 1.37 (0.27, 6.95) 3.06 (1.02, 9.18) 
Azithromycin 18 66 0.73 (0.42, 1.28) 0.61 (0.35, 1.05) 
Phenylpropanolamine 
HCl 
7 9 2.83 (0.98, 8.16) 2.68 (1.06, 6.80) 
Niacin 122 408 0.87 (0.69, 1.10) 0.85 (0.69, 1.05) 
Labetalol 4 5 1.63 (0.40, 6.61) 2.58 (0.86, 7.74) 
Acetaminophen 701 2318 0.97 (0.83, 1.14) 0.96 (0.84, 1.10) 
Ibuprofen 309 873 1.16 (0.98, 1.37) 1.16 (1.00, 1.34) 
Aspirin 61 164 1.21 (0.87, 1.69) 1.25 (0.94, 1.66) 
Butalbital 5 8 1.51 (0.47, 4.81) 2.07 (0.74, 5.77) 
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Venlafaxine 9 9 3.67 (1.39, 9.70) 2.38 (0.95, 5.96) 
Lutein 40 93 1.21 (0.81, 1.82) 1.16 (0.81, 1.66) 
Lycopene 22 38 1.72 (0.98, 3.05) 1.31 (0.77, 2.22) 
Barley Grass 6 10 1.65 (0.56, 4.84) 2.13 (0.84, 5.38) 
Herbal Tea 10 32 1.69 (0.77, 3.73) 1.84 (0.96, 3.52) 
Progesterone 51 76 1.44 (0.95, 2.18) 1.25 (0.89, 1.76) 
Iodine 258 753 1.14 (0.95, 1.37) 1.17 (1.00, 1.37) 
Levothyroxine Sodium 31 61 1.38 (0.86, 2.23) 1.33 (0.88, 2.01) 
  
 Abbreviations: OR, odds ratio; CI, confidence interval. 
a
 Medication exposure is reported for the period from 1 month before to 4 months after 
conception.  
b 
Odds ratios are adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, parity, 
sub-fertility, study site, and year of due date.  
 
 
In the final sub-analysis the association between isolated hypospadias and maternal use of 
specific medications, excluding mothers who reported illicit drug use was evaluated (Table 5). 
Overall, results from the sub-analysis were similar to the aORs from the primary analysis, 
presented in Table 2. The aORs for cephalexin (aOR 3.50; 95% CI 1.13, 10.87), 
phenylpropanolamine HCl (aOR 2.85; 95% CI 1.10, 7.38), and ibuprofen (aOR 1.20; 95% CI 
1.03, 1.39) were stronger in the sub-analysis than the primary analysis. 
 
Table 5: Association of Isolated Hypospadias with Maternal Use of Specific Medications, 
Excluding Mothers Reporting Illicit Drug Use, National Birth Defects Prevention Study, October 
1997 to December 2007.
a,b
  
 
Medication Exposure Exposed 
Cases  
Exposed 
Controls 
aOR
c
 (95% CI)  
Sub-Analysis 
aOR (95% CI) 
Primary Analysis 
     
Cephalexin 6 7 3.50 (1.13, 10.87) 3.06 (1.02, 9.18) 
Azithromycin 18 66 0.61 (0.35, 1.07) 0.61 (0.35, 1.05) 
Phenylpropanolamine 
HCl 
10 9 2.85 (1.10, 7.38) 2.68 (1.06, 6.80) 
Niacin 154 414 0.86 (0.69, 1.06) 0.85 (0.69, 1.05) 
Labetalol 8 5 2.51 (0.76, 8.25) 2.58 (0.86, 7.74) 
Acetaminophen 918 2381 0.95 (0.82, 1.09) 0.96 (0.84, 1.10) 
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Ibuprofen 406 870 1.20 (1.03, 1.39) 1.16 (1.00, 1.34) 
Aspirin 90 177 1.23 (0.92, 1.64) 1.25 (0.94, 1.66) 
Butalbital 8 8 2.06 (0.74, 5.75) 2.07 (0.74, 5.77) 
Venlafaxine 9 10 2.51 (0.99, 6.37) 2.38 (0.95, 5.96) 
Lutein 52 103 1.10 (0.76, 1.58) 1.16 (0.81, 1.66) 
Lycopene 24 43 1.23 (0.72, 2.10) 1.31 (0.77, 2.22) 
Barley Grass 9 10 1.93 (0.74, 5.00) 2.13 (0.84, 5.38) 
Herbal Tea 16 31 1.91 (0.97, 3.77) 1.84 (0.96, 3.52) 
Progesterone 93 103 1.26 (0.90, 1.77) 1.25 (0.89, 1.76) 
Iodine 354 773 1.17 (1.00, 1.37) 1.17 (1.00, 1.37) 
Levothyroxine Sodium 44 71 1.30 (0.86, 1.98) 1.33 (0.88, 2.01) 
  
Abbreviations: OR, odds ratio; CI, confidence interval. 
a
 Medication exposure is reported for the period from 1 month before to 4 months after 
conception.  
b
 Mothers reporting illicit drug use any time 1 month preconception through month 3 
postconception were excluded. 
c 
Odds ratios are adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, parity, 
sub-fertility, study site, and year of due date. 
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Chapter V 
DISCUSSION AND CONCLUSION 
5.1 Discussion 
After adjusting for potential confounders, the results of this analysis suggested an 
increased risk of second- or third-degree hypospadias among infants delivered to women who 
took cephalexin, phenylpropanolamine HCl, ibuprofen, and venlafaxine during the period of 1 
month before to 4 months after conception.  
 This analysis illustrates that the association between isolated hypospadias and medication 
exposure during the periconceptional period and early pregnancy is sensitive to confounding by 
the factors we considered. The majority of the 89 odds ratios estimated in the crude analysis 
were attenuated in the adjusted analysis. Restricting analyses based on a potentially confounding 
factor is an alternative method to multivariable models for controlling confounding. Relative to 
the primary analysis, associations between hypospadias and maternal use of cephalexin and 
venlafaxine became stronger, and for phenylpropanolamine HCl were attenuated, in sub-analyses 
in which infants with a positive family history of hypospadias were excluded, though overall, 
estimates did not change appreciably. In sub-analyses excluding low birth weight infants and 
multiple births, the associations with venlafaxine and phenylpropanolamine HCl were stronger; 
attenuated results were observed for several of the medications including cephalexin. Excluding 
mothers who reported illicit drug use resulted in aOR estimates similar overall to those observed 
in the primary analysis, although stronger associations were observed for cephalexin, 
phenylpropanolamine HCl, and ibuprofen. 
Cephalexin, a first generation cephalosporin antibiotic used frequently during pregnancy, 
is indicated for the treatment of susceptible bacterial infections including respiratory tract 
infections, otitis media, skin and skin structure infections, bone infections, and genitourinary 
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tract infections.
48,49
 The observation of a statistically significant association between cephalexin 
and hypospadias risk in this study differs from several older published reports which found no 
association between use of cephalexin and congenital defects or toxicity in newborns.
50
 More 
recently published studies have reported an association between cephalexin and cephalosporin 
use and risk of certain birth defects.
48,50,51
 However, an association with hypospadias has not 
been previously reported. 
 Phenylpropanolamine HCl, also known as PPA, is a synthetic sympathomimetic amine 
that was historically used frequently in many OTC weight loss products and as a decongestant in 
cough and cold medications. Since November 2000, the United States Food and Drug 
Administration (FDA) has been working to remove PPA from all drug products and requested 
that all drug companies discontinue marketing products containing PPA, as a result of the FDA 
Nonprescription Drugs Advisory Committee’s determination of an association between PPA and 
hemorrhagic stroke.
52,53
 Heinonen et al. evaluated the association between prenatal PPA 
exposure and congenital malformations in the Collaborative Perinatal Project, which monitored 
50,282 mother-child pairs. There were 4 observed hypospadias cases among 726 pregnant 
women who had PPA exposure during their first trimester, resulting in a standardized relative 
risk of 1.63 (95% CI 0.44-4.13).
54
 Blood vessels of the uterus, which are normally fully dilated, 
contain alpha-adrenergic receptors.
50
 It is possible then that use of PPA, which stimulates alpha- 
and beta-adrenergic receptors, could cause constriction of uterine vessels and reduce uterine 
blood flow, potentially resulting in poor intrauterine growth, a risk factor for hypospadias.
27,40,50
       
 Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), works by decreasing the 
activity of the enzyme cyclooxygenase (COX), which results in the inhibition of prostaglandin 
synthesis.
49
 Animal models suggest that the action of testosterone on embryonic genitalia 
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involves prostaglandins and that prenatal exposure to COX inhibitors inhibits masculinization of 
male genitalia.
55
 Additionally, COX inhibitors, including ibuprofen, have been found to be 
endocrine disruptors, as well as to affect steroid hormone synthesis in rainbow trout.
56
 Studies 
have also shown that another COX inhibitor, aspirin, inhibits androgen response to hCG 
stimulation in normal human adult males.
57
 Therefore, exposure to COX inhibitors during critical 
periods of gestation could affect normal urogenital development in males.
58
 In another study 
utilizing NBDPS data from 1997-2004,
59
 NSAID use during the first trimester and the risk of 
birth defects was evaluated, and they found no association between first trimester ibuprofen use 
and hypospadias. There were, however, fewer cases classified as exposed to ibuprofen in that 
study (n=99) compared to this one (n=423), due to them having fewer years of data, an exposure 
window defined as the estimated day of conception through 3 months afterward, their exclusion 
of mothers with preexisting diabetes mellitus, and their separation of women who could not 
characterize their frequency of NSAID use in the first trimester into a separate “as needed” 
category. While an association between hypospadias and maternal use of ibuprofen has not been 
previously reported, an association has been observed between prenatal use of the mild 
analgesics acetaminophen, aspirin, and ibuprofen and risk of congenital cryptorchidism, 
60
 a 
genital abnormality commonly observed with hypospadias.
27
 
 Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of 
depression and anxiety.
49
 Despite evidence that there is substantial transfer of venlafaxine across 
the placenta,
61
 there are very few published reports describing the use of venlafaxine during 
human pregnancy.
50
 In a review by Salvatore Gentile, no malformations were observed in data 
obtained from the UK Drug Safety Research Unit that reported the outcomes of 39 women who 
took venlafaxine during pregnancy.
62
 Likewise, in a prospective study in which there were ten 
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cases exposed to venlafaxine during pregnancy, all obstetrical findings were normal during each 
of the pregnancies and no congenital abnormalities were diagnosed in the infants in their first 12 
months.
63
 Yet, concurring with the association between venlafaxine exposure and hypospadias 
found here, in a study by Einarson and colleagues, in which data on 150 women exposed to 
venlafaxine during pregnancy in seven pregnancy counseling centers were compared with data 
from studies of pregnant women who were exposed to selective serotonin-reuptake inhibitors 
(SSRIs) and to women who received non-teratogenic drugs, it was observed that among the 
women exposed to venlafaxine during pregnancy, two babies were born with major 
malformations, one of which was hypospadias; drug-specific ORs were not estimated in the 
study.
64
 
 Several analyses using NBDPS data have been published on the association of a specific 
medication and the spectrum of birth defects included in the NBDPS. The findings in this 
analysis coincide with several of these other studies that observed no significant association 
between risk of hypospadias and exposure to loratadine, 
65
 certain SSRIs,
66
 ephedra,
67
 certain 
antihistamines,
68
 acetaminophen,
69
 bupropion,
70
 certain opioid analgesics,
71
 certain 
corticosteroids,
72
 or certain antihypertensives.
73
  
This analysis did not replicate the findings reported by Anderka and colleagues regarding 
an association of hypospadias with proton pump inhibitors (PPIs) or steroids used in the 
treatment of nausea and vomiting in pregnancy. It should be noted, however, that in their study, 
PPIs and steroids were analyzed as combined medication groups and drug-specific ORs were not 
calculated.
19
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5.2 Study Strengths and Limitations 
 This study had numerous strengths. The data came from a large, population-based study 
that allowed for sufficient statistical power to analyze numerous medication exposures during the 
critical period for male urethral development. The multi-center study design also provided 
geographic diversity. In addition, there was consistent and detailed case ascertainment, with 
cases reviewed and classified by clinical geneticists, and differentiation of isolated and multiple 
hypospadias cases.  
 However, the study is not without potential limitations. Maternal medication use in the 
analyses was not exclusive and mothers may have been using multiple medications at the same 
time. Therefore, there is potential for confounding from concurrent medication use. Inability to 
examine the dose of medications is another limitation. Also, while overall this was a large study, 
there were a relatively small number of exposed infants for some of the medication components, 
which could potentially affect analyses results. Medication exposures were determined by 
maternal report during the interview; hence recall bias is another potential limitation of the study. 
However, to improve recall NBDPS mothers were provided with a pregnancy calendar before the 
interview to help them respond to questions about the timing of exposure more accurately, in the 
way that they best remember, such as by date, month of pregnancy, or trimester. Some 
medications were specifically queried, while others were reported in response to treatment for 
reported maternal medical conditions. With 89 different medication components examined in this 
analysis, another limitation is multiple testing. Therefore, these results should be considered 
hypothesis-generating rather than hypothesis-testing, with the aim to help generate justification 
for future analyses. Furthermore, while numerous medications were examined in this analysis, 
there are still many medications that were not evaluated and these results do not provide 
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definitive information on the overall association between maternal medication use and risk of 
hypospadias. Finally, because the study population was limited to second- and third-degree 
isolated hypospadias cases it was not possible to examine if there may be an association between 
specific medication exposures and milder forms of hypospadias. 
5.3 Conclusion and Recommendations 
In conclusion, the findings presented here suggest there may be an association between 
maternal use of cephalexin, phenylpropanolamine HCl, ibuprofen, and venlafaxine during the 
periconceptional period and early pregnancy and an increased risk of second- or third-degree 
hypospadias in male infants. Future studies on the associations observed here and on medications 
not included in this study are warranted. Further investigation into medications associated with a 
risk of hypospadias will allow clinicians and women of childbearing age to make more informed 
decisions regarding the prescribing and intake of certain medications, by adding to the body of 
knowledge on the effects of medication use during pregnancy.           
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